Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 9/2020

01-09-2020 | Cranial MRI | Letter to the Editor

Cerebrospinal fluid MOG-antibodies in anti-NMDA receptor encephalitis with leptomeningeal enhancement

Authors: Eiichiro Amano, Akira Machida, Naomi Kanazawa, Takahiro Iizuka

Published in: Neurological Sciences | Issue 9/2020

Login to get access

Excerpt

IgG antibodies against myelin oligodendrocyte glycoprotein (MOG) are associated with acute demyelinating encephalomyelitis [1], neuromyelitis optica, cortical encephalitis [2, 3], or aseptic meningitis [4]. MOG-antibodies are usually examined in serum but rarely detected exclusively in cerebrospinal fluid (CSF) [5]. The antibodies can be detected in patients with overlapping demyelinating syndromes and anti-NMDA receptor (NMDAR) encephalitis [6‐8], but the role of CSF MOG-antibodies in patients with NMDAR-antibody-positive aseptic meningitis remains unclear. Herein, we report a case of recurrent anti-NMDAR encephalitis with leptomeningeal enhancement, in which MOG-antibodies were retrospectively identified in the CSF. …
Appendix
Available only for authorised users
Literature
1.
Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, Chandratre S, Hemingway C, Jacob A, Vincent A, Leite MI, Waters P, Palace J (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140:3128–3138CrossRef
2.
Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, Sato DK, Nishiyama S, Misu T, Kuroda H, Aoki M, Fujihara K (2017) MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 4:e322CrossRef
3.
Fujimori J, Takai Y, Nakashima I, Sato DK, Takahashi T, Kaneko K, Nishiyama S, Watanabe M, Tanji H, Kobayashi M, Misu T, Aoki M, Fujihara K (2017) Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. J Neurol Neurosurg Psychiatry 88:534–536CrossRef
4.
Nagabushana D, Shah R, Pendharkar H, Agrawal A, Kulkarni GB, Rajendran S, Alladi S, Mahadevan A (2019) MOG antibody seropositive aseptic meningitis: a new clinical phenotype. J Neuroimmunol 333:476960CrossRef
5.
Yanagida A, Iizuka T, Nagai T, Usui R, Kaneko J, Akutsu T, Hanajima R, Kanazawa N, Nishiyama K (2017) MOG-IgG-positive multifocal myelitis with intrathecal IgG synthesis as a spectrum associated with MOG autoimmunity: two case reports. J Neurol Sci 382:40–43CrossRef
6.
Titulaer MJ, Höftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T, Benson LA, Shu H, Irioka T, Hirano M, Singh G, Cobo Calvo A, Kaida K, Morales PS, Wirtz PW, Yamamoto T, Reindl M, Rosenfeld MR, Graus F, Saiz A, Dalmau J (2014) Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol 75:411–428CrossRef
7.
Kaneko K, Sato DK, Misu T, Kurosawa K, Nakashima I, Fujihara K, Aoki M (2014) Anti-N-methyl-D-aspartate receptor encephalitis with multiphasic demyelination. Ann Neurol 76:462–464CrossRef
8.
Zhou L, ZhangBao J, Li H, Li X, Huang Y, Wang M, Zhao C, Lu J, Lu C, Li Y, Quan C (2017) Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies. Mult Scler Relat Disord 18:90–92CrossRef
9.
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091–1098CrossRef
Metadata
Title
Cerebrospinal fluid MOG-antibodies in anti-NMDA receptor encephalitis with leptomeningeal enhancement
Authors
Eiichiro Amano
Akira Machida
Naomi Kanazawa
Takahiro Iizuka
Publication date
01-09-2020
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 9/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04343-3

Other articles of this Issue 9/2020

Neurological Sciences 9/2020 Go to the issue

COVID-19

A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients

Letter to the Editor

A case of anti-gamma-aminobutyric acid-B receptor encephalitis coexisting with ankylosing spondylitis

Review Article

Spinocerebellar ataxia type 48: last but not least

COVID-19

The emotional impact of COVID-19 outbreak in amyotrophic lateral sclerosis patients: evaluation of depression, anxiety and interoceptive awareness

Review Article

Sensory stimulation to improve arousal in comatose patients after traumatic brain injury: a systematic review of the literature

Review Article

Rest tremor in dystonia: epidemiology, differential diagnosis, and pathophysiology